WP3:Toxicology studies of lead monoclonal antibodies

The goal of this workpackage will be to evaluate the safety of the anti-HCV and anti-SR-BI mAb by:

  • Defining the specificity of the anti-HCV mAb using an industrial-standard tissue array

  • Assessing the capacity of the anti-SR-BI mAb to interfere with SR-BI function in lipid metabolism

  • Evaluating if the anti-SR-BI mAb increases the risk of atherosclerosis and determine any ischemic disease risk

  • Studying the possible toxic effects of the anti SR-BI mAb on the various cells, tissues and organs

Pre-clinical testing will conform to accepted and published European Medicine Agency and FDA guidelines